Comparative Pharmacology
Head-to-head clinical analysis: BANAN versus CEFIXIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BANAN versus CEFIXIME.
BANAN vs CEFIXIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BANAN is a potassium-channel opener that hyperpolarizes smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
500 mg orally twice daily for 7-14 days.
400 mg orally once daily or 200 mg orally every 12 hours for 7–14 days; uncomplicated gonorrhea: 400 mg orally as a single dose
None Documented
None Documented
2.5 hours (normal renal function); prolonged to 6-8 hours in severe renal impairment
Clinical Note
moderateCefixime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefixime."
Clinical Note
moderateCefixime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefixime."
Clinical Note
moderateWarfarin + Cefixime
"Warfarin may increase the anticoagulant activities of Cefixime."
Clinical Note
moderatePhenprocoumon + Cefixime
Terminal elimination half-life is 3-4 hours in patients with normal renal function; extends to 11-15 hours in moderate renal impairment (CrCl 20-40 mL/min) and up to 20 hours in severe impairment.
Renal: 70% unchanged; biliary: 20%; fecal: 10%
Renal excretion of unchanged drug accounts for 50-60% of elimination; biliary/fecal elimination accounts for 10-20%.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefixime."